Endocrine Abstracts

A previous study demonstrate that chronic tadalafil administration (2 mg/kg per day) was able to prevent some, but not all, penile alterations induced by long-term (3 months) bilateral cavernous neurotomy (BCN) in the rat. In particular, in vitro acetylcholine responsiveness and reduced eNOS and nNOS expression were not preserved, while PDE5 down-regulation, along with muscle/fiber ratio and hypoxygenation (hypoxyprobe) were significantly restored by chronic tadalafil (...

Epididymis (epi) is a sex steroid-sensitive duct provided with spontaneous motility, allowing sperm transport. We previously demonstrated that human epi expresses a high abundance of mRNA for ER-alpha and ER-beta. We demonstrated that in epi estrogens up-regulate either oxytocin (OT) responsiveness, acting at the receptor level, and responsiveness to endothelin-1 (ET-1), another well-known stimulator of epididymal motility. However, we did not find any significant change eithe...

Expanding brown adipose tissue is a potential therapeutic strategy to counteract insulin resistance and metabolic syndrome (MetS). Farnesoid X receptor (FXR) and Takeda G protein-coupled receptor 5 (TGR5) activation enhances insulin sensitivity, suggesting the capacity of FXR/TGR5 agonists to promote brown differentiation in adipose tissue. Treatment with increasing doses of the dual FXR/TGR5 agonist INT-767 (3, 10, 30 mg/Kg bw, daily for 5 days a week, by oral gavage, for 12 ...

The potential therapeutic applications of targeting brown adipose tissue open new clinical avenues in fighting against metabolic pathologies. However, due to the limited brown depots in adult humans, dramatically reduced after birth, solid cell models to study human brown adipogenesis and its pathophysiological regulation are urgently needed.In our study, we characterized a novel human model of brown adipose stem cells, hfB-ASC, derived from fetal inters...

Farnesoid X receptor (FXR) and Takeda G protein-coupled receptor 5 (TGR5) are interesting pharmacological targets for the treatment of liver and metabolic diseases. FXR-deficient mice on a high-fat diet (HFD) exhibit massive hepatic steatosis, necro-inflammation and fibrogenesis. Moreover, pharmacological activation of TGR5 in mice promotes protective mechanisms in biliary epithelial cells and inhibits hepatic and systemic inflammation. Thus, we hypothesized that a FXR/TGR5 du...

Liver and visceral ectopic fatty tissue disposition is a major metabolic derangement leading to type 2 diabetes, hypertension, dyslipidaemia, recapitulated in the metabolic syndrome (MetS). We have demonstrated that the selective FXR agonist obeticholic acid (OCA, INT-747) ameliorates the metabolic profile and reduces visceral adipose tissue (VAT) in a high-fat diet (HFD)-induced rabbit model of MetS. We now report the effects of OCA treatment in HFD (0.5% cholesterol and 4% p...

The exposure of cells to high glucose concentrations is considered a determinant of diabetic neuropathy. Conversely, members of the Insulin-like Growth Factor (IGF) system are well known neurotrophic factors. Here, we investigated the effects of constant and intermittent high glucose concentrations on IGF-I and IGF Binding Proteins (IGFBPs) in human neuroblast long-term cell cultures (FNC). We first demonstrated that FNC express the IGF-I receptor, and express and release in t...